Figure 4 | Scientific Reports

Figure 4

From: JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans

Figure 4

Inhibition of ex vivo IL-23–stimulated IL-17A production in rat whole blood following oral dosing with JNJ-77242113. IL-17A levels produced in whole blood samples (diluted 5 × in media) after addition of 4 ng/mL IL-1β were subtracted from IL-17A levels produced with 20 ng/mL IL-23 and 4 ng/mL IL-1β. Doses below 1 mg/kg (not shown; 0.03, 0.1, and 0.3 mg/kg) showed no significant difference from vehicle control. Bars represent medians and error bars denote interquartile ranges. Data from 5 experiments were combined. Plasma samples from each animal were analyzed using an LC–MS/MS method and dilution adjusted to report concentrations of JNJ-77242113 in the assay. IL interleukin, LC–MS/MS liquid chromatography tandem mass spectrophotometry, ns not significant, PO orally. *P < 0.05, ****P < 0.0001.

Back to article page